Drug Profile

MSP 2020

Alternative Names: MSP-2020

Latest Information Update: 17 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mindset Pharma
Class Indoles; Neuropsychotherapeutics; Pyrrolidines; Small molecules
Mechanism of Action Serotonin 5-HT2A receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Mental disorders

Most Recent Events

22 Oct 2025 Otsuka Pharmaceutical plans a phase I trial in Healthy volunteers in Netherlands (PO) (CTIS2025-522930-29-00) (EUCT2025-522930-29-00)
01 Jan 2024 Mindset Pharma has been acquired and merged into Otsuka America Pharmaceutical (Otsuka America Pharmaceutical website, January 2024)
05 Oct 2022 Mindset Pharma plans IND enabling studies for MSP 2020

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com